THOMAS SEOH

Thomas Seoh is an entrepreneur and executive who has held senior leadership positions in public and private pharmaceutical, biotech, and medical device companies for three decades. He currently serves as EVP of the Kitalys Institute and CEO of Kinexum.

​​​​​

After practicing corporate law in New York and London and serving as General Counsel for several companies, including the ICN Pharmaceuticals group in Costa Mesa, he joined Guilford Pharmaceuticals in Baltimore, which developed and commercialized GLIADEL®, a wafer for glioblastoma multiforme, and developed the propofol pro-drug LUSEDRA®, and small molecules for Parkinson’s disease. Thomas began as Guilford’s VP, General Counsel, and Secretary, and later served as SVP Corporate and Commercial Development. He was then CEO of venture-backed Faust Pharmaceuticals in Strasbourg, France, developing a repurposed compound in Phase II for Parkinson’s patients, a re-positioned molecule for Duchenne muscular dystrophy, and a GPCR drug discovery platform.  

​

He has served on various boards, including a startup therapeutic company targeting mitochondrial ion channels and transporters for ‘metabesic’ and cancer indications, as well as a public Cedars Sinai spin-out with an ex vivo liver dialysis device in clinical development. Additionally, he has been held C-suite leadership positions in medical device companies developing a novel mechanical thrombectomy device for deep vein thrombosis and stroke, a state-of-the-art neurocatheter, and the first plant-based skin substitute wound dressing. He is a former member of the Hopkins Alliance, an industry-faculty advisory board at Johns Hopkins School of Medicine, and an industry advisory board at University of Maryland Baltimore County.  

​

Thomas holds an AB in Philosophy and History and a JD from Harvard University.